A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants
with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose
escalation and safety expansion which determines the optimal dose and maximum number of
tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Biosciences International Sàrl Incyte Corporation